Related Experiment Video

Updated: Sep 10, 2026

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

Reimbursement claims analysis of outcomes with carvedilol and metoprolol

Aileen B Luzier1, Laura A Antell, Li-Ling Chang

  • 1School of Pharmacy, University of Buffalo, NY 14260-1200, USA. luzier@acsu.buffalo.edu

The Annals of Pharmacotherapy
|March 16, 2002
PubMed

Insights

Carvedilol significantly reduced hospitalizations and total costs in heart failure (HF) patients compared to metoprolol. Despite higher drug expenses, carvedilol offers greater clinical benefits and cost-effectiveness for HF management.

Area of Science:

  • Cardiology
  • Pharmacoeconomics
  • Health Services Research

Background:

  • Heart failure (HF) management involves balancing clinical efficacy with healthcare resource utilization.
  • Beta-blockers are cornerstone therapies for HF, with differing receptor blockade profiles.
  • Understanding the comparative cost-effectiveness of different beta-blockers is crucial for optimizing patient care.

Purpose of the Study:

  • To compare resource use and associated costs between carvedilol and metoprolol in heart failure patients.
  • To evaluate the impact of selective (metoprolol) versus comprehensive (carvedilol) beta-adrenergic blockade on healthcare utilization.
  • To determine the overall economic implications of using carvedilol versus metoprolol in HF management.

Main Methods:

  • Retrospective analysis of healthcare claims data from 6 healthcare plans.
  • Inclusion of patients diagnosed with HF and treated with either carvedilol or metoprolol for 6 months.
  • Utilized a modified Charlson index for comorbidity assessment and logistic regression for hospitalization risk analysis.

Main Results:

  • Carvedilol patients showed significantly lower rates of total hospitalizations (36.0% vs. 62.3%) and emergency department visits (23.7% vs. 42.5%) compared to metoprolol patients.
  • Carvedilol treatment was associated with a 65% reduction in the risk of any hospitalization (adjusted OR 0.35).
  • Despite higher pharmacy costs for carvedilol ($1677 vs. $1322), total healthcare costs were significantly lower ($8100 vs. $14475).

Conclusions:

  • Comprehensive adrenergic blockade with carvedilol may offer superior clinical benefits in heart failure patients compared to selective beta-blockade with metoprolol.
  • Carvedilol therapy, while associated with increased pharmacy expenditures, leads to reduced overall healthcare costs in HF management.
  • These findings support carvedilol as a cost-effective treatment option for heart failure, potentially improving patient outcomes and reducing system burden.
Abstract

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...